Nanoplatform-Enhanced Therapies for Adenoid Cystic Carcinoma: Integrating Pathobiology, Microenvironment Modulation, and Synergistic Treatment Strategies
- 1Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, 450008, People’s Republic of China
- 2HNHC Key Laboratory of Radiation Oncology for Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, 450008, People’s Republic of China
Abstract
Yana Ma,1,2 Weijia Zhu,1,2 Hang Yuan,1 Ruican Nie,1,2 Wen Luo,1,2 Hongtao Hu11Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, 450008, People’s Republic of China; 2HNHC Key Laboratory of Radiation Oncology for Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, 450008, People’s Republic of ChinaCorrespondence: Hongtao Hu, Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, 450008, People’s Republic of China, Email [email protected]: Adenoid cystic carcinoma (ACC) is an indolent yet aggressive malignancy characterized by perineural invasion, local recurrence, and distant metastasis. Current clinical management, primarily surgical resection and postoperative radiotherapy, offers limited efficacy, and systemic therapies have yielded unsatisfactory outcomes for recurrent and metastatic ACC, largely due to its unique molecular drivers and a structurally and immunologically complex tumor microenvironment (TME). Nanoplatforms, with their tunable physicochemical properties, surface functionalization, and designable stimuli-responsive release capabilities, offer a promising strategy for overcoming the barriers that hinder the efficacy of conventional therapies, which is crucial for improving treatment outcomes. In this review, we first summarize the key pathogenic features of ACC and the critical TME components, including immunosuppressive landscape, aberrant vasculature, stroma, and neural niches. We then outline rational design of nanoparticle system suited for ACC, highlighting active targeting and responsive strategies. Finally, we highlight recent advances in nanoplatform-based ACC therapies, from enhanced chemotherapy, radiotherapy, and ablation, to emerging therapeutic mechanisms, such as ferroptosis, cuproptosis, and TME reprogramming via cGAS-STING activation. By bridging ACC pathobiology with nanomedicine engineering, this review aims to provide insights that may accelerate the development of comprehensive and personalized therapeutic approaches for this challenging disease.Keywords: adenoid cystic carcinoma, nanoparticles, molecular drivers, tumor microenvironment, personalized therapy
Related
- Biomimetic sequential targeted nanoplatform for synergistic thrombolysis in ischemic stroke.
- Tumor Microenvironment-Triggered Dual-Prodrug Nanoplatform for Augmented Photodynamic Therapy: Self-Quenched Photosensitizer Activation and Nitric Oxide-Mediated Sensitization
- Synergistic Pore Microenvironment Engineering in Zinc Metal–Organic Frameworks for High SF 6 /N 2 Selectivity and Humidity‐Resistant Trace SF 6 Capture
- Multi-configuration synergistic modulation of MXene/poly-Schiff-base/Fe3O4 aerogels with enhanced microwave absorption, thermal insulation, and flame retardancy
- Integrating microenvironment tailoring into molecular electrocatalysis
BibTeX
@article{ma2026nanoplatformenhanced,
title = {{Nanoplatform-Enhanced Therapies for Adenoid Cystic Carcinoma: Integrating Pathobiology, Microenvironment Modulation, and Synergistic Treatment Strategies}},
author = {Yana Ma and Weijia Zhu and Hang Yuan and Ruican Nie and Wen Luo and Hongtao Hu},
journal = {International Journal of Nanomedicine},
year = {2026},
month = oct,
doi = {10.2147/ijn.s638880},
url = {https://www.dovepress.com/nanoplatform-enhanced-therapies-for-adenoid-cystic-carcinoma-integrati-peer-reviewed-fulltext-article-IJN},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Nanoplatform-Enhanced Therapies for Adenoid Cystic Carcinoma: Integrating Pathobiology, Microenvironment Modulation, and Synergistic Treatment Strategies
AU - Yana Ma
AU - Weijia Zhu
AU - Hang Yuan
AU - Ruican Nie
AU - Wen Luo
AU - Hongtao Hu
PY - 2026
DA - 2026/10/01
JO - International Journal of Nanomedicine
DO - 10.2147/ijn.s638880
UR - https://www.dovepress.com/nanoplatform-enhanced-therapies-for-adenoid-cystic-carcinoma-integrati-peer-reviewed-fulltext-article-IJN
AB - Yana Ma,1,2 Weijia Zhu,1,2 Hang Yuan,1 Ruican Nie,1,2 Wen Luo,1,2 Hongtao Hu11Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, 450008, People’s Republic of China; 2HNHC Key Laboratory of Radiation Oncology for Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, 450008, People’s Republic of ChinaCorrespondence: Hongtao Hu, Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, 450008, People’s Republic of China, Email [email protected]: Adenoid cystic carcinoma (ACC) is an indolent yet aggressive malignancy characterized by perineural invasion, local recurrence, and distant metastasis. Current clinical management, primarily surgical resection and postoperative radiotherapy, offers limited efficacy, and systemic therapies have yielded unsatisfactory outcomes for recurrent and metastatic ACC, largely due to its unique molecular drivers and a structurally and immunologically complex tumor microenvironment (TME). Nanoplatforms, with their tunable physicochemical properties, surface functionalization, and designable stimuli-responsive release capabilities, offer a promising strategy for overcoming the barriers that hinder the efficacy of conventional therapies, which is crucial for improving treatment outcomes. In this review, we first summarize the key pathogenic features of ACC and the critical TME components, including immunosuppressive landscape, aberrant vasculature, stroma, and neural niches. We then outline rational design of nanoparticle system suited for ACC, highlighting active targeting and responsive strategies. Finally, we highlight recent advances in nanoplatform-based ACC therapies, from enhanced chemotherapy, radiotherapy, and ablation, to emerging therapeutic mechanisms, such as ferroptosis, cuproptosis, and TME reprogramming via cGAS-STING activation. By bridging ACC pathobiology with nanomedicine engineering, this review aims to provide insights that may accelerate the development of comprehensive and personalized therapeutic approaches for this challenging disease.Keywords: adenoid cystic carcinoma, nanoparticles, molecular drivers, tumor microenvironment, personalized therapy
SN - 1178-2013
SN - 1176-9114
ER -